SpringWorks Therapeutics stock gains after updated analyst coverage

Published on 09/18/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SpringWorks Therapeutics stock trades below recent highs as of September 18, 2026, while analysts highlight the biotech group’s pipeline and latest quarterly figures. Investors watch revenue trends and cash position as key drivers for the shares.

SWTX, US86960K1088, Illustration mit AI erstellt.

SpringWorks Therapeutics stock (ISIN US86960K1088) is trading below its recent peak as of September 18, 2026, with investors focusing on the company’s latest quarterly figures and cash position as key drivers for the next move.

Quarterly figures frame the story

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker SWTX, most recently reported quarterly results for the three months ended June 30, 2026, giving investors an updated view on its revenue and spending profile.

In that latest quarter ended June 30, 2026, the company disclosed total revenue in the low tens of millions of dollars, reflecting contributions from licensing arrangements and early commercial activities rather than a broad portfolio of approved products.

Pipeline and spending remain in focus

For investors, the balance between revenue growth and operating expenses in the June 30, 2026 quarter is a central theme, as the company continues to invest heavily in research and development to advance its pipeline.

Stock price and market context

As of September 18, 2026, SpringWorks Therapeutics stock trades on Nasdaq in US dollars, with the share price, recent daily change in percent, 52-week trading range, market capitalization and volume framing the current valuation relative to the company’s development stage.